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Abstract
Targeted angiostatic therapy receives major attention for the treatment of cancer and exudative age-related macular degeneration (AMD).
Photodynamic therapy (PDT) has been used as an effective clinical approach for these diseases. As PDT can cause an angiogenic
response in the treated tissue, combination of PDT with anti-angiogenic compounds should lead to improved therapy. This study was
undertaken to test the clinically used small molecule kinase inhibitors Nexavar® (sorafenib), Tarceva® (erlotinib) and Sutent® (sunitinib)
for this purpose, and to compare the results to the combination of Visudyne®-PDT with Avastin® (bevacizumab) treatment. When top-
ically applied to the chicken chorioallantoic membrane at embryo development day (EDD) 7, a clear inhibition of blood vessel develop-
ment was observed, with sorafenib being most efficient. To investigate the combination with phototherapy, Visudyne® -PDT was first
applied on EDD11 to close all 100 m vessels. Application of angiostatics after PDT resulted in a significant decrease in vessel
regrowth in terms of reduced vessel density and number of branching points/mm2. As the 50% effective dose (ED50) for all compounds
was approximately 10-fold lower, Sorafenib outperformed the other compounds. In vitro, all kinase inhibitors decreased the viability of
human umbilical vein endothelial cells. Sunitinib convincingly inhibited the in vitro migration of endothelial cells. These results suggest
the therapeutic potential of these compounds for application in combination with PDT in anti-cancer approaches, and possibly also in
the treatment of other diseases where angiogenesis plays an important role.
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Introduction
Angiogenesis is a key step in physiological processes such as
wound healing and the female reproductive cycle, as well as in
pathologies such as cancer, rheumatoid arthritis and exudative
AMD [1, 2]. The first successful large-scale treatment option for
exudative AMD was verteporfin (Visudyne® ) PDT [3]. This
approach is based on light-induced angio-occlusion after injection
of a photosensitizer. Several studies have shown that PDT can
occlude experimental subfoveal choroidal neovascularization
(CNV) with minimal damage to the surrounding retina [4].
Unfortunately, following verteporfin-PDT, a later angiogenic
response can occur that limits the value of the treatment [5]. This
has lead to renewed interest in understanding the mechanism of
PDT and improving the basis of it [6, 7].
Angiogenesis occurs through an intricately regulated cascade
of events involving, among other factors, the families of VEGFs,
fibroblast growth factors (FGF), and also platelet-derived growth
factor (PDGF) and epidermal growth factor (EGF) [8, 9]. Their
receptors are linked to a tyrosine kinase domain that takes part in
signalling pathways affecting endothelial cell (EC) proliferation,
migration or differentiation ability [10], thus facilitating blood ves-
sel regrowth. It is well-established that various pathologies are
caused by overstimulation of tyrosine kinase activity and the intra-
cellular signalling pathways that they activate. The activity does
#This manuscript is dedicated to the memory of Dr. Jean-Pierre Ballini
(1943–2010) who was a member of the Medical Photonics Group for
many years and whose personality and work was invaluable to the
 laboratory and many of its endeavours.
*Correspondence to: Patrycja NOWAK-SLIWINSKA,
Urology Department, University Hospital (CHUV), 
Lausanne, CH-1011, Switzerland. 
Tel.: 41-21-6935169
Fax: 41-21-6935110
E-mail: Patrycja.Nowak-Sliwinska@epfl.ch
1554 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
not have to be restricted to ECs, as PDGF signalling also appears
to regulate the recruitment of support cells (smooth muscle
cells/pericytes) to the vascular bed [11].
A number of kinase inhibitors are presently on the market and
their application in clinical medicine is being elucidated [12]. Several
kinase inhibitors are approved in cancer treatment: Gleevec® /
imatinib (Novartis AG, Basel, Switzerland) for chronic myelogenous
leukaemia and gastrointestinal stromal tumours [13], Tasigna® /
nilotinib (Novartis) for chronic myelogenous leukaemia, including
the patients resistant or intolerant to imatinib [14], Sutent®  /sunitinib
(Pfitzer Icl., New York, NY, USA) for renal cell carcinoma and gas-
trointestinal stromal tumours [15], Nexavar® /sorafenib (Bayer
HealthCare and Onyx Pharmaceuticals, Inc.) for renal cell carcinoma
and hepatocellular carcinoma [16], and Iressa®/gefitinib
(Astra/Zeneca, London, UK) for non–small cell lung cancer [17].
More than 20 other kinase inhibitors are currently in clinical trials,
also for other diseases than cancer [18]. These inhibitors target
either mainly single receptors, for example erlotinib, which binds
EGFR [19], or are broad spectrum inhibitors, for example sorafenib,
which targets B-Raf/VEGFR-2/VEGFR-3/PDGFR-b/FLT-3/c-KIT/RAF
[20] or sunitinib inhibiting VEGFR/PDGFR-b/c-KIT/FLT-3 [21].
As inhibition of angiogenesis has been recognized as a promis-
ing treatment strategy of angiogenic diseases, an increasing num-
ber of anti-angiogenic compounds are being developed for use in
either mono- or combination therapies [22]. Thus, in this study we
investigated the efficacy of selected kinase inhibitors, both on the
morphological and molecular level, following angio-occlusive PDT.
An attractive model for studying angiogenesis after PDT is the
chorioallantoic membrane (CAM) of the chicken embryo. Study of
photodynamic angio-occlusion and reperfusion, as well as neofor-
mation of vessels can be performed in situ and in real time
[23–26]. This in vivo pre-clinical model has the advantage of hav-
ing a thin, planar vascular network, which is well-accessible to
PDT and PDT in combination with adjuvants, added either topically
or intravenously (i.v.) [27].
In this study we adopted a previously described automated
quantification method [25] to assess the vessel regrowth rate in
the PDT-treated area of the CAM, using high-quality fluorescence
angiography of the revascularization in the PDT-treated area. The
method was used to show the prolonged angio-occlusive effect
after PDT, when topically applying the angiogenesis inhibitors.
Materials and methods
Materials and chemicals
Avastin® was obtained from Genentech (San Francisco, CA, USA) and
Sutent® from Pfizer Inc. (New York, NY, USA). Nexavar®and Tarceva®were
obtained from LC Laboratories (Woburn, MA, USA). Visudyne® (the lipo-
somal formulation of verteporfin) was generously provided by Novartis
Ophthalmics (Hettlingen, Switzerland). Fluorescein isothiocyanate dextran
(FITC–dextran, 20 kD) was purchased from Sigma-Aldrich (Buchs,
Switzerland). The 0.9% NaCl solution, which was used as a solvent for the
kinase inhibitors, or by itself as the control, is a product of Bichsel AG
(Interlaken, Switzerland). Embryos were obtained from Animalco AG
(Staufen, Switzerland). India ink was purchased at Pelikan (Witzikon,
Switzerland) and filtered through a sterile cellulose acetate membrane (0.2
m pores; Renner GmbH, Darmstadt, Germany). The injections in the CAM
were performed with MicroliterTM syringes equipped with 33-gauge metal
Hub (N) needles, both from Hamilton (Reno, NV, USA).
Developmental CAM and quantification 
of the angiogenic response
In this assay, the anti-angiogenic efficacy of the compounds was tested in
the physiologically developing CAM model between EDD7 and EDD9, as
previously described in detail [25]. Briefly, compounds were applied topi-
cally twice (each time 20 l) on EDD7 and EDD8. The concentrations
ranged from 0.1 to 300 M (this corresponds to 0.001–2.6 g/embryo for
erlotinib and 0.0013–3.9 g/embryo for sorafenib), from 2 to 1000 M
(0.0213–10.65 g/embryo) for sunitinib, and from 0.2 to 80 M for beva-
cizumab (0.6–238 g/embryo). The control eggs received 0.9% NaCl twice
(each time 20 l). On EDD9, the CAMs were visualized in ovo by means of
FITC-dextran (25 mg/ml, 20 l) epi-fluorescence angiography and subse-
quently analysed by the image-processing quantification method described
later. At least five eggs were tested per condition.
Visudyne®  -PDT in combination with topically
administrated tyrosine kinase inhibitors
We also combined Visudyne®  -PDT with the subsequent topical administra-
tion of the following angiogenesis inhibitors: bevacizumab (2–20 M cor-
responding to 6–60 g/embryo), sunitinib (2–20 M corresponding to
0.02–0.2 g/embryo), sorafenib (2–20 M corresponding to 0.026–0.26
g/embryo), erlotinib (1–20 M corresponding to 0.01–0.2 g/embryo).
These anti-angiogenic compounds were deposited topically to the surface
of the CAM in the form of liquid drops of 20 l within a polyethylene ring
(diameter 5 mm; wall thickness 0.5 mm, 1 mm height). All tested com-
pounds were applied twice, immediately after PDT (20 l), and 24 hrs after
PDT (20 l). As mentioned before, fluorescence angiographies were taken
24 and 48 hrs after either PDT or combined treatment.
Microscopy and image acquisition
Microscopic observation of CAM vasculature, as well as the light irradia-
tion during PDT, were performed with an epi-fluorescence Eclipse 600 FN
microscope equipped with a Plan Apo 4/0.2, working distance of 20 mm
or Plan Fluor 10/0.3, working distance of 16 mm objectives (Nikon,
Tokyo, Japan). Illumination was provided by a 100 W high pressure Hg-arc
lamp, as described before [23]. Light doses were adjusted with neutral
density filters and measured with a calibrated Field-Master GS power meter
(Coherent, Santa Clara, CA, USA). For exciting and detecting Visudyne®,
the microscope was equipped with a BV-2A filter set (ex  420  20 nm,
em 	 470 nm; Nikon). For detecting FITC, light was filtered for excitation
at 470  20 nm and a long-pass emission filter was used for detection of
the fluorescence ( 	 520 nm; Nikon). Fluorescence images were acquired
with an F-view II 12-bit monochrome Peltier-cooled digital charge-coupled
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device camera driven with analySIS DOCU software from Soft Imaging
System (Munster, Germany) [26, 28].
The in ovo CAM model for Visudyne®-PDT
Fertilized chicken eggs were labelled and transferred into a hatching incu-
bator with a relative air humidity of 65% and a temperature of 37
C, as
described previously [23, 25]. On EDD3, a hole of approximately 3 mm in
diameter was opened in the eggshell and covered with a laboratory wrap-
ping film, Parafilm® (Pechiney, Menasha, WI, USA) to prevent dehydration
and possible infections.
On EDD11, the egg opening was extended to 3 cm in diameter, and
Visudyne® was i.v. administered into the main vessel of the CAM. Eggs were
placed under the epi-fluorescence microscope and 1 min. after injection, the
CAM was irradiated with a light dose of 20 J/cm2 (ex  420  20 nm) and
irradiance 50 mW/cm2. The irradiation area was limited to 0.02 cm2 by an
optical diaphragm within the area defined by the polyethylene ring used for
the topical drug administration. Visudyne®-based fluorescence angiogra-
phies were taken before and right after irradiation (ex  420  20 nm). The
PDT conditions we used led to angio-occlusion efficiency for the CAM ves-
sels similar to those observed clinically after Visudyne®-PDT in the human
eye, that is similar diameters of vessels were closed in the CAM as in the
human CNV. Photodynamic therapy induced closure of the CAM-vasculature
is defined as optimal when vessels with a diameter 70 m are closed,
while leaving the larger vessels open [23, 29]. Fluorescein isothiocyanate
based fluorescence angiographies were taken 24 and 48 hrs after PDT after
i.v. injection of 20 l of FITC-dextran (20 kD, 25 mg/ml). Prior to the fluores-
cence angiography, an India ink injection in the extra-embryonic cavity was
performed to block optical interference from the autofluorescence originat-
ing in the embryo below the CAM. For these angiographies, we used light
from a filtered Hg-arc lamp for excitation (ex  470  20 nm), and a long-
pass emission filter (em 	 520 nm), as described later [23].
Quantitative image analysis
Fluorescence angiographies of the CAM at EDD9 were analysed using a
macro written for ImageJ, as previously described [25]. Briefly, images
were quantified using a two-step processing algorithm. The first phase
extracted the large vessels with a threshold-based segmentation. The sec-
ond phase extracted the small vessels and capillaries using a rolling-ball
background filter. The results from both phases were then combined and
skeletonized to describe the vessel connectivity.
In this study, the above-mentioned macro was adapted to quantify the
PDT-treated areas of the CAM (EDD13). Four concentric regions-of-inter-
ests were defined to be able to quantify the treatment efficacy from the bor-
der to the center (Fig. 3B). Area 4, the most external zone is located on the
edge of the PDT-treated zone and gets revascularized first. Area 1 is the
most inner location within the PDT-treated area, and gets revascularized
last. To monitor the vascular network and the regrowth of the vasculature
within the PDT-treated area, three selected descriptors were calculated by
our software. The descriptors are defined as follows: Descriptor 1 is the
number of branching points/mm2. Descriptor 2 is a delimiter of vascular
mesh size, expressed as the 3rd quartile of the shortest distance from any
pixel to the nearest segment and given in micrometers. This descriptor
gives information on the capacity of oxygenation of the tissue areas, allow-
ing the generation of a hypoxia map (Fig. 3). Descriptor 3 represents the
vessel density. This parameter is based on the number of black pixels in the
skeletonized image, scaled per surface of each analysed ring and
expressed as a  percentage of this surface.
RNA isolation, cDNA synthesis and primers
Total RNA was isolated from CAM sections treated with mono- or combi-
nation therapies using the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA)
according to the supplier’s protocol. RNA quality and quantity were
checked by spectrophotometry (NanoDrop; Thermo Scientific, Breda, The
Netherlands), and 1000 ng RNA was used as input for first-strand cDNA
synthesis using an iScript cDNA synthesis kit (Bio-Rad Laboratories,
Veenendaal, The Netherlands) according to the manufacturers’ instruc-
tions. Reactants were diluted to 50 l and stored at 20
C until use.
The primers were specific for chicken (Gallus gallus) sequences 
and selected based on the following requirements: (i) GC content of
approximately 55%, (ii) primer melting temperature of approximately 60
C,
(iii) preferably no G at the 5’ end, (iv) avoid runs of more than three iden-
tical nucleotides and (v) amplicon length of approximately 100 nucleotides.
Specificity and cross-reactivity were checked with the Basic Local
Alignment Search Tool (BLAST; http:// www.ncbi.nlm.nih.gov/BLAST).
Primers were synthesized by Eurogentec (Liège, Belgium) and targeted
against -actin (Actin-), cyclophilin-A (Cyclo-A), vascular endothelial
growth factor A (VEGFA), vascular endothelial growth factor receptors 
1 and 2 (VEGFR1, -2), neuropilin-2 (NRP2), basic fibroblast growth factor
(bFGF), integrin 3 (ITGB3) and galectin 1 (GAL1).
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR (qRT-PCR) was performed in 25 l reac-
tions, containing 1 iQ SYBR Green supermix (Bio-Rad Laboratories), 200
nM forward and reverse primer (Fig. 7C) and 1.5 l cDNA. Reactions were
run on a CFX96 thermal cycler (Bio-Rad Laboratories), and consisted of an
initial denaturation for 10 min. at 95
C followed by 50 cycles of 15 seconds
at 95
C and 1 min. at 60
C. Following each run, melting curves were gen-
erated to verify specific product formation. Data were analysed using CFX
Manager software (Bio-Rad Laboratories) and the expression of each tar-
get gene was quantified relative to the expression of the reference genes
(Actin- and Cyclophilin-A) [30].
Cells and reagents
Human umbilical vein ECs (HUVEC) were isolated from fresh human umbil-
ical cord veins and maintained in RPMI-1640 (Invitrogen) supplemented
with 10% human serum, 10% FCS, 1% glutamin (Invitrogen), 100 IU/ml
penicillin (Sigma-Aldrich, St. Louis, MO, USA), and 100 g/ml strepto-
mycin (Sigma-Aldrich) as previously described [31]. Cells were cultured in
a highly humidified atmosphere with 5% CO2 at 37
C.
Proliferation assay
Endothelial cells (5  103 cells/well) were seeded in gelatin-coated 96-well
cell culture plates as described previously [32]. Briefly, 24 hrs after seed-
ing, culture medium with or without compounds was added and cells were
grown for a further 72 hrs. Cell viability was assessed using the CellTiter-
Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA).
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Wound assay (migration)
The migration capability of ECs was measured using the wound assay [33].
In brief, HUVEC were grown to confluence in gelatin-coated wells and
‘scratch wounds’ (with an approximate width of 350 m) were made in the
monolayer by removing cells with a sterile scratch tool (Peira Scientific
Instruments, Beerse, Belgium). Cells were washed with PBS and the medium
was replaced by fresh medium containing 10 ng/ml bFGF (Tebu-Bio,
Heerhugowaard, The Netherlands) and incubated with or without tyrosine
kinase inhibitors. Automated image acquisition was performed with a Leica
DMI3000B microscope in combination with UGR grabbing software (DCI
Labs, Peira Scientific Instruments). Bright field images taken at 5 magnifi-
cation were processed for computational analysis of scratch sizes using UGR
Scratch Assay 6.2 software (DCI Labs, Peira Scientific Instruments).
Statistical analysis
Values are given as mean values  S.E.M. Data are represented as aver-
ages of independent experiments, performed in duplicate or triplicate.
Statistical analyses were done using the Student’s t-test. P-values  0.05
were considered statistically significant.
Results
Inhibition of developmental angiogenesis 
in the CAM
We tested the angiostatic activity of the kinase inhibitors: erlotinib,
sorafenib and sunitinib in vivo in the CAM assay, and compared
the results with those obtained after treatment with bevacizumab
(Avastin®). Dose ranges of compounds were administered topically
on the CAM on EDD7, when vascularization of the membrane
starts to become exponential. Treatment was repeated on EDD8
and the vascularization of the CAM was analysed and quantified on
EDD9. Treatment with the compounds at low concentrations
resulted in the presence of small avascular zones in the capillary
bed along the larger blood vessels (Fig. 1). At higher concentra-
tions, as of 30–50 M for TKIs and 10 M for bevacizumab, loss
of vascular hierarchy was observed, as well as complete absence
of vasculature within large areas of the CAM (Fig. 1C, arrows indi-
cate the avascular zones, appearing as black areas in the fluores-
cence angiographies). For all inhibitors tested we observed a
dose-dependent anti-angiogenic activity. As compared to the
untreated control, statistically significant differences for both
reported descriptors were observed as of 100 M (erlotinib P 
0.045, sorafenib P  0.028, sunitinib P  0.048). Digital analysis
of the images revealed a slightly better activity for sorafenib over
the other kinase inhibitors (versus sunitinib shown in Fig. 1 at 
300 M; P  0.044 for branching points per mm2 and P  0.027
for mean mesh size). Assessment of the number of branching
points per mm2 (Fig. 1A) and the relative mesh size (Fig. 1B)
showed for sorafenib an ED50 of 100 M, while this was approxi-
mately 300 M for erlotinib and sunitinib. The ED50 of bevacizumab
in this assessment was 80 M. Representative fluorescence
angiographies of dose-dependent morphological changes are shown
in Figure 1C for sunitinib (upper row) and bevacizumab (lower row).
Morphological and molecular response 
in the CAM after PDT
The CAM model is often used as a model for PDT-induced angio-
occlusion [23, 34]. We observed that Visudyne® -PDT, applied at
EDD11, induced an efficient closure of the vasculature (Fig. 2A
and B), as well as an angiogenic response in the treated tissue,
compromising the angio-occlusive effect of therapy. Vascular
regrowth in the CAM is visible 24 hrs after PDT (Fig. 2B) and is
completed 48 hrs after PDT (Fig. 2C). The morphology of the
neovessels was observed to be completely different from the nor-
mal vasculature and larger vascular meshes were observed, as
compared to the non-PDT treated areas of the CAM. To investi-
gate and prove the induction and regulation of angiogenesis after
PDT, we determined gene expression before and 24 hrs after PDT
(EDD12) of a set of endothelial angiogenesis markers, such as
galectin-1 (GAL1) and integrin -3 (ITGB3), and the angiogene-
sis related genes for neuropillin-2 (NRP2), VEGFR1, -2, VEGF and
bFGF. Expression was compared to the reference genes Actin-
and Cyclophilin-A. We noticed a PDT-mediated induction of the
endothelial angiogenesis markers galectin-1 and integrin-3, as
well as of neuropillin and the VEGF receptors.
Post-PDT vascular regrowth inhibition 
by angiostatic kinase inhibitors
To maintain and prolong the PDT-induced vaso-occlusive effect, we
tested a series of clinically used angiostatic kinase inhibitors.
Topical administration of 20 l of 20 M of sunitinib, sorafenib or
erlotinib immediately after PDT, resulted in a statistically significant
(P  0.05) prolongation of PDT-induced vascular occlusion (seen
as black zones on the angiographies). Figure 3A shows representa-
tive angiographies taken 48 hrs after PDT without (left image) or in
combination with topical administration of compounds. Results are
compared with combination treatment with bevacizumab (right
image). Interestingly, while regrown vasculature in the PDT treated
area shows different morphology as compared to the original
 vascular bed, the morphology of the regrown vasculature in the
presence of different compounds varied as well. Topical administra-
tion of sunitinib prevented the vascular regrowth in the central part
of the PDT-treated area. Topical administration of sorafenib turned
out to completely inhibit angiogenic response within PDT-treated
zone. However, the morphology of the vasculature outside the 
PDT-treated was slightly affected as well. Both larger vessels 
and capillary bed remained occluded 48 hrs after treatment.
Administration of the same concentration of erlotinib revealed a
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similar efficacy as sunitinib, however more sprouts were observed
at the edge of PDT-treated area. Moreover, larger vessels seemed to
be less sensitive to the treatment and were reperfused at 48 hrs.
Bevacizumab inhibited angiogenesis, but to a lesser extend than the
kinase inhibitors. For digital imaging and analysis of the vasculature
in the PDT-treated area, we developed a quantitative image process-
ing method to process the fluorescence angiographies. A schematic
diagram of the method is shown in Figure 3B. The method allows
independent analysis of circular regions of the PDT area, using three
different descriptors, that is number of branching points/mm2, rela-
tive vascular mesh size and vessel density. We found that all com-
pounds inhibited vascular regrowth dose dependently, as assessed
by all three descriptors. The most significant differences between
the compounds were obvious in the inner most zones of the PDT-
treated area (zones 1 and 2) and quantification of it is shown for
zone 1 for two concentrations of the drugs (2 and 20 M; Fig. 3C).
The most distinguished results were visible for 20 M, revealing
superior activity for sorafenib (P  0.025 versus sunitinib) over the
other tested agents. All results obtained for combination therapy
were statistically significant as compared to PDT alone. Moreover,
we observed a statistically significant difference for applied
 concentrations of sorafenib after PDT (see asterisks in Fig. 3C) for
Fig. 1 Inhibition of developmental angiogenesis in the CAM by kinase inhibitors and bevacizumab. (A, B) Digital analysis of the vasculature in the CAM
after treatment with kinase inhibitors or bevacizumab. (A) Inhibition of angiogenesis represented as inhibition of relative number of branching points/mm2
as a function of drug concentration. Asterisks represent the statistical significance of the higher activity of sorafenib over sunitinib at 100 M of the com-
pounds. (B) Inhibition of angiogenesis represented as an increase of mean vascular mesh size as a function of drug concentration. (C) Angiographic
images of the developmental CAM treated with indicated concentrations (expressed in M) of sunitinib (upper row) and bevacizumab (lower row). The
vasculature is visualized by FITC-dextran fluorescence angiography (25 mg/kg, 20 kD, ex  470 nm, em 	 520 nm) on EDD9. The bar in the right image
of the upper row represents 200 m and is valid for all images. Arrows indicate the avascular zones in the CAM, visible as a black areas in angiographies.
Error bars represent standard error of the mean.
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branching points (mm2) with P  0.032, relative vascular mesh size
(m) with P  0.027, and vessel density with P  0.026.
The vascular regrowth was also monitored by quantitative  
real-time PCR analysis of the expression of VEGFR-1 and -2, being
vascular angiogenesis markers. Expression of both VEGF recep-
tors was up-regulated by PDT. The kinase inhibitors also induced
their expression and co-treatment with kinase inhibitors did not
change that (Fig. 4).
TKIs, but not bevacizumab, inhibit endothelial
cell growth and migration in vitro
To compare the above results with the exclusive activity of the
compounds on endothelial cells, we tested the compounds for
their ability to inhibit human endothelial cell growth and migration.
All kinase inhibitors decreased the viability of HUVEC with ED50
values of 2 M (erlotinib), 3 M (sunitinib) and 50 M (sorafenib).
As expected, bevacizumab did not inhibit endothelial cell growth at
any of the concentrations applied (Fig. 5A).
As the second indication of the compound’s activities on EC
function, migration assays were performed with HUVEC. As
shown in Figure 5B, only sunitinib dose-dependently diminished
the motility of EC at concentrations upwards from 1 M, with
an ED50-value of approximately 3 M. Figure 5C shows exam-
ples of the wounds in the confluent HUVEC layer before (left
image) and after 8 hrs of incubation with (1 or 30 M) or with-
out sunitinib.
Discussion
This study describes that PDT-induced vascular occlusion in the
CAM can be prolonged by topical co-treatment with clinically used
angiostatic small molecule kinase inhibitors. This maybe a rele-
vant observation in the field of ocular pathology, as treatment of
AMD is nowadays performed by regular intravitreal injection of
ranibizumab (Lucentis® ) [35]. The CAM model has been shown to
be a useful model to study retinal vasculature [23, 36]. It was
 previously observed that PDT can induce significant angio-
occlusion of the exposed CAM vasculature in vessels with a diam-
eter of 100 m. This process coincided with induction of an
angiogenic response resulting in complete revascularization of the
angio-occluded area over a period of 48 hrs [23]. We have previ-
ously demonstrated that angiostatic treatment of the CAM with
Fig. 2 Impact of PDT on morphological and
molecular level of the mature CAM 24 hrs
after treatment. Representative angiogra-
phy images of the CAM before (A), 24 hrs
(B) and 48 hrs after PDT (C). Vasculature in
picture A is visualized by Visudyne® fluo-
rescence angiography (0.20 mg/kg embryo
weight, ex  420 nm, em 	 470 nm).
Pictures B and C are visualized by FITC-
dextran fluorescence angiography (25
mg/kg, 20 kD, ex  470 nm, em 	 520
nm). PDT was performed at a light dose of
20 J/cm2 and an irradiance of 50 mW/cm2.
Black background colour is obtained by
India ink injection (30 l) into the extra-
embryonic cavity right under the treated
CAM area. Circles indicate the PDT-treated
area. The scale bar in A applies for all pan-
els. (D) Real-time quantitative RT-PCR
molecular profiling of the CAM 24 hrs after
PDT. Relative transcript expression in the
CAM versus the reference genes Actin-
and Cyclophilin-A for the following treat-
ment groups: control (CTRL), galectin-1
(GAL1), integrin 3-subunit (ITGB3), neu-
ropillin-2 (NRP2), VEGFR-1, -2, VEGF and
bFGF. Error bars represent standard error of
the mean.
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ranibizumab (Lucentis® ) or bevacizumab (Avastin® ) after PDT
can increase the duration of the closure of the vasculature [29].
We now demonstrate that similar results can be achieved with
small molecule anti-angiogenic kinase inhibitors, which are 
currently used in the clinic.
As the CAM model is often used as a model for PDT-induced
angio-occlusion, and the study of post-PDT revascularization, we
developed an ImageJ-based vessel-quantification tool to digitally
analyse vascular architecture and growth. As the revascularization
of the CAM occurs from the edge of the PDT-treated area, we have
now adopted the previously described software [25] to create four
concentric circular areas. In each area the vascularization is mon-
itored and quantified as a function of time after PDT, normalized
per area. Regrowth of vessels starts from the existing vessels in
the most outward circular area, and progresses into the other
areas localized more towards the center of the PDT-treated area of
the CAM surface. Various descriptors, such as vascular density
and branching points per mm2 (Materials and methods), are used
to quantify and characterize the revascularization in these areas.
Results from this vessel quantification tool can be used to
 quantitatively test for optimal angio-occlusion and to optimize the
combination of photodynamic angio-occlusion with angiogenesis
Fig. 3 Sustained photodynamic vaso-occlusion by angiogenesis inhibitors. (A) Typical fluorescence angiographies taken 48 hrs after Visudyne®-PDT
(0.20 mg/kg embryo weight, ex  420 nm, em 	 470 nm; light dose of 20 J/cm2 and an irradiance of 50 mW/cm2, drug-light interval 1 min.) alone,
and combination therapy of PDT with the topically administered angiogenesis inhibitors: sunitinib, sorafenib, erlotinib or bevacizumab. All agents were
applied twice (immediately and 24 h post PDT) to a surface of 0.2 cm2. The vasculature is visualized by FITC-dextran fluorescence angiography (25 mg/kg,
20 kD, ex  470 nm, em 	 520 nm). (B) Schematic representation of the image processing quantification method. An original fluorescence angiogra-
phy (left image) undergoes the skeletonization process as visualized on the block scheme (right). The skeletonized image is also shown as a map of
 distance of each pixel to the closest vascular segment, also referred to as ‘potential oxygenation map’. Black areas represent avascular zones. The PDT
area is indicated and divided into circular areas, 1 indicates the innermost area, 4 indicates the most peripheral area. (D) Schematic representation of 
the image processing procedure used to characterize the CAM vascular network. It indicates how image B was obtained from the information of image A.
(C) Quantifications of three descriptors for two concentrations of the drugs. Means are shown, error bars represent standard error of the mean.
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inhibitors. Following the angio-occlusive PDT, treatment with
bevacizumab or kinase inhibitors resulted in significant inhibition
of the post-PDT vascular regrowth. A change in density, as well as
architectural differences of the vasculature after treatment was
evident from all descriptors. The number of branching points in
the vasculature (descriptor 1) was significantly repressed,
whereas the parameter representing vascular mesh size was
increased, suggesting a decrease in potential oxygenation, and the
vessel density (descriptor 3). The results showed that the kinase
inhibitors were very efficient inhibitors of vascular regrowth, and
their activities were at least comparable to the activity of beva-
cizumab. Interestingly, sorafenib showed a significantly better
activity as compared to treatment with bevacizumab, resulting in a
significantly slower revascularization.
At the molecular level, it was observed that PDT treatment effi-
ciently induced the expression of VEGFR1 and VEGFR2. Also the
expression levels of VEGF and bFGF tended to go up, although not
significantly. Co-treatment with angiogenesis inhibitors was found
to further force the cells into an angiogenesis program [23]. These
results demonstrate that both PDT and inhibitors of angiogenesis
force the vasculature into a compensatory mechanism of angio-
genesis stimulation.
For use in the treatment of eye diseases such as exudative
AMD, there may be a number of advantages for the use of small
molecule kinase inhibitors over bevacizumab. First of all, treat-
ment with bevacizumab depends so far on intraocular injections,
probably because of the low-tissue penetration of the antibody. As
this is an invasive procedure, the use of a small molecule that may
be administered through eye drops or sustained drug delivery sys-
tems [37–39] could have a significant benefit. It is anticipated that
(i) systemic side-effects known for angiostatic agents will not
occur because of the local, that is low dose, administration, (ii)
that resistance to the drug will not evolve because the angiogene-
sis process is not tumour driven [40] and that (iii) vascular nor-
malization is induced locally resulting in enhanced efficacy of the
combination with PDT [41].
To support the assumption that the activity seen in the CAM is
based on an activity on endothelial cells, and to be able to com-
pare activities of the different anti-angiogenic compounds, we
performed proliferation and migration assays making use of
HUVEC. Although all kinase inhibitors inhibited proliferation with
ED50’s of 3–30 M, sunitinib was the only kinase inhibitor that
significantly inhibited migration with ED50 as low as 1–3 M. It is
interesting to observe that sorafenib, while inhibiting migration
and proliferation only at a higher dose, seems to be the most
effective inhibitor in both the developmental and the PDT CAM
assays. A possible explanation for this phenomenon might be the
in vitro versus in vivo difference, or the species difference in
these assays, as sorafenib might have a higher affinity for chicken
receptors as compared to their human counterparts. It is
assumed that the activity of the compound is mainly on the
endothelium, however, it cannot be excluded that the effect is
indirect through an activity on epithelial cells, fibroblasts or vas-
cular support cells. It should be realized that in this study we
applied the small molecule kinase inhibitors topically on the CAM.
This was done because to some extent this may be simulating
application through eye drops. However, we know that i.v. injec-
tions of the kinase inhibitors works very efficiently as well, and
seems to need even lower concentrations of the drug (Nowak-
Sliwinska et al., unpublished data).
Fig. 4 Molecular regulation of VEGF receptors after PDT in combination with treatment with angiogenesis inhibitors. Quantitative real-time PCR using
chicken-specific primers for the VEGFR1 and VEGFR2. Mean relative expressions are shown  standard error of the mean.
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An alternative explanation for the good activity of sorafenib is
the broader kinase spectrum, because VEGFR3 and B-Raf are
kinase targets that are not shared by the other drugs. It remains to
be seen if the benefit of sorafenib holds when it comes to applica-
tion for eye diseases in patients.
Another interesting finding of this research is that the
inhibitory dose of all angiogenesis inhibitors tested was approxi-
mately 10-fold lower in the PDT-induced angiogenesis, as com-
pared to the developmental angiogenesis. We have previously
shown a similar phenomenon for ruthenium-arene-based com-
pounds possessing anti-angiogenic properties [27]. We hypothe-
size that this shows that developmental angiogenesis is a more
robust process that is probably more intricately regulated, and
more well-balanced, than the process that follows the sudden PDT
challenge. It is furthermore tempting to speculate that whereas
developmental angiogenesis is regulated by VEGF, angiopoietins,
EGF, PDGF, PlGF, etc., PDT-induced angiogenesis is mainly driven
by VEGF, as is the case in tumours. This would then result in a vas-
culature that has the tortuosity of tumour vasculature, an observa-
tion that we have published recently [23].
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